Details for Patent: 9,315,811
Which drugs does patent 9,315,811 protect, and when does it expire?
Patent 9,315,811 protects DAWNZERA (AUTOINJECTOR) and is included in one NDA.
This patent has five patent family members in four countries.
Summary for Patent: 9,315,811
| Title: | Methods for modulating kallikrein (KLKB1) expression |
| Abstract: | Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema. |
| Inventor(s): | Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod |
| Assignee: | Ionis Pharmaceuticals Inc |
| Application Number: | US14/124,630 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 9,315,811
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | 9,315,811 | ⤷ Start Trial | PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,315,811
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012267546 | ⤷ Start Trial | |||
| Canada | 2838984 | ⤷ Start Trial | |||
| European Patent Office | 2717923 | ⤷ Start Trial | |||
| European Patent Office | 3320922 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
